Month: May 2025

Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

Written by Customer Service on May 12, 2025. Posted in Earnings Releases And Operating Results.

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025 MET-097o, an oral formulation of MET-097i, has been accelerated and alternate oral candidate MET-224o is on track, with four-week data for selected lead expected in late 2025 $588 million cash and cash equivalents support runway into 2027 NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) — Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported first quarter 2025 financial results and continued...

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

Written by Customer Service on May 12, 2025. Posted in Public Companies.

Wa’el HashadWa’el Hashad, CEO, LongeveronLongeveron selected as a Top 40 Semifinalist based on the feasibility of its stem cell therapy Stem cell therapy laromestorcel being evaluated as potential treatment for Alzheimer’s disease and HLHS, a rare pediatric disease and orphan-designated indicationMIAMI, May 12, 2025 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has been selected as a Semi-Finalist Team and one of the Top 40 Teams receiving a $250,000 Milestone 1 Award in the XPRIZE Healthspan competition. “We’re proud to be a Semifinalist team of XPRIZE Healthspan, a 7-year, $101 million global competition that aims to revolutionize...

Annual Report for the year ended 31 December 2024 and Notice of Meeting

Written by Customer Service on May 12, 2025. Posted in Public Companies.

Octopus Titan VCT plc Annual Report for the year ended 31 December 2024 and Notice of Meeting Further to the announcement of annual results for the year ended 31 December 2024, Octopus Titan VCT plc (the ‘Company’) announces that the Annual Report has been posted or otherwise made available to shareholders. A copy of the Annual Report is also available to view on the Company’s website at http://www.octopusinvestments.com The Annual Report includes the Notice of Meeting for the Annual General Meeting of the Company to be held on 19 June 2025. The Annual Report, together with the Form of Proxy, has been submitted to the Financial Conduct Authority’s Electronic Submission System and is available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism For further information please contact: Rachel PeatOctopus Company...

Eviden Awarded Contract for “Kaufhaus des Bundes – Next Generation” Project by the Procurement Office of the Federal Ministry of the Interior (BeschA)

Written by Customer Service on May 12, 2025. Posted in Public Companies.

Press Release Eviden Awarded Contract for “Kaufhaus des Bundes – Next Generation” Project by the Procurement Office of the Federal Ministry of the Interior (BeschA) Together with veenion, Eviden is redesigning the ‘KdB NG’ procurement platform for more than 480 federal authorities and federal-related institutions Berlin, Deutschland, and Paris, France – May 12, 2025 – Eviden, the Atos Group business leading in digital, cloud, big data and security and IT partner veenion GmbH announce the successful signing of a contract for the modernization project “Kaufhaus des Bundes – Next Generation (KdB NG)”. The KdB NG will replace the existing system and create a convenient and modern procurement portal. This new platform will fully digitize the electronic procurement for over 480 federal authorities and federal-related...

Emerging Markets Report: A Milestone for Mycelium

Written by Customer Service on May 12, 2025. Posted in Public Companies.

Underreported D.E.A. Letter and Policy Position Could be a Game Changer for Mushroom Enthusiasts An Emerging Markets Sponsored Commentary ORLANDO, Fla., May 12, 2025 (GLOBE NEWSWIRE) — At the Emerging Market Report we are comprised of a team of veteran journalists, authors, former stock brokers, financial professionals, and unabashed opportunists who all come together to publish these tidy missives on our client profiles. We are constantly searching for impactful news that could be gamechangers for the Companies we cover. And we sure missed a big piece. So did just about everybody else. That big piece could be a major catalyst for Hypha Labs (OTCQB: FUNI) which makes the first at-home and commercial patent-pending mushroom ingredient maker of its kind. The elevator pitch is that Hypha Labs is to mushrooms as the clever Keurig was,...

Gilat Expands and Adds to its ESA Antenna Portfolio with a Successful Test Flight of ESR-2030Ku on Eutelsat OneWeb Low Earth Orbit (LEO) Network

Written by Customer Service on May 12, 2025. Posted in Public Companies.

This New ESA terminal complements Stellar Blu Sidewinder solutions, positioning Gilat to serve both business and defense aviation markets with a comprehensive multi-orbit offering PETAH TIKVA, Israel, May 12, 2025 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, announced today the successful completion of a series of test flights featuring its ESR-2030Ku electronically steered antenna (ESA). Conducted in collaboration with Gogo, which will be the exclusive distributor of the antenna for the business aviation and defense markets, the tests demonstrated outstanding performance of the ESA on the OneWeb Low Earth Orbit (LEO) network. The ESR-2030Ku—designed for mobility and engineered for efficiency—delivered full-duplex connectivity...

Dorel Reports First Quarter 2025 Financial Results

Written by Customer Service on May 12, 2025. Posted in Earnings Releases And Operating Results.

Dorel Juvenile reports strong performance Dorel Home taking further steps to return to profitabilityMONTRÉAL, May 12, 2025 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) today announced its financial results for the first quarter ended March 31, 2025. First quarter revenue was US$320.5 million, down 8.7%, from US$351.1 million a year ago. Reported net loss for the quarter was US$25.3 million or US$0.77 per diluted share compared to US$17.6 million or US$0.54 per diluted share a year ago. The reported net loss for the quarter includes total restructuring costs of US$1.6 million and as such, adjusted net loss1 was US$23.6 million or US$0.72 per diluted share compared to US$16.9 million or US$0.52 per diluted share for the first quarter a year ago.   ‟Dorel Juvenile had a strong start to 2025, with another quarter...

OTC Markets Group Welcomes Northisle Copper and Gold Inc. to OTCQX

Written by Customer Service on May 12, 2025. Posted in Public Companies.

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Northisle Copper and Gold Inc. (TSX-V: NCX; OTCQX: NTCPF), a Vancouver-based sustainable mineral resource company, has qualified to trade on the OTCQX® Best Market. Northisle Copper and Gold Inc. upgraded to OTCQX from the Pink® market. Northisle Copper and Gold Inc. begins trading today on OTCQX under the symbol “NTCPF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards...

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

Written by Customer Service on May 12, 2025. Posted in Earnings Releases And Operating Results.

Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway into 2027, with optionality to extend into 2028WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025. “We have made considerable progress in our Phase 2 LOTUS trial in hidradenitis suppurativa (HS) with site activations, screenings and enrollment progress all in line with our original projections as we have begun to meaningfully climb the enrollment curve. As such, we believe...

K92 Mining Announces Q1 2025 Financial Results – Record Quarterly Revenue, Net Income, Operating Cash Flow, EBITDA and Net Cash Position

Written by Customer Service on May 12, 2025. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, May 12, 2025 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce financial results for the three months ended March 31, 2025. ProductionStrong quarterly production of 47,817 ounces gold equivalent (“AuEq”)(1) or 45,735 oz gold, 1,141,379 lbs copper and 34,085 oz silver, achieving the second highest quarterly production on record. Production exceeded budget and delivered a 74% increase from Q1 2024. Net of by-product credit basis cash costs of $559/oz gold and all-in sustaining costs (“AISC”) of $1,010/oz gold(3) and co-product basis cash costs of $616/oz AuEq and AISC of $1,048/oz AuEq(3). Strong metallurgical recoveries in Q1, of 95.8% for gold and 95.1% for copper, both marking the second highest quarterly recoveries on record. Recoveries compare...

Month: May 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals